Publication des résultats d’études cliniques

Les informations ci-dessous ainsi que les liens correspondant aux données cliniques répondent aux exigences des articles 71 à 73 de l’Ordonnance sur les médicaments (Ordonnance sur les médicaments, OMéd) et complètent les informations publiées en lien avec l’autorisation suisse des médicaments correspondants.

VAXNEUVANCE®

Vaccin pneumococcique polyosidique conjugué (15-valent, adsorbé). Solution injectable.

1 dose (0,5 ml) contient:

  • Polyoside pneumococcique de sérotype 11,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 31,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 41,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 51,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 6A1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 6B1,2 4,0 microgrammes
  • Polyoside pneumococcique de sérotype 7F1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 9V1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 141,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 18C1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 19A1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 19F1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 22F1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 23F1,2 2,0 microgrammes
  • Polyoside pneumococcique de sérotype 33F1,2 2,0 microgrammes

1 Conjugué à la protéine vectrice CRM197. La protéine CRM197 est une toxine diphtérique mutante non toxique (issue de Corynebacterium diphtheriae C7) exprimée par recombinaison dans Pseudomonas fluorescens.
2 Adsorbé sur phosphate d’aluminium utilisé comme adjuvant.

1 dose (0,5 ml) contient 125 microgrammes d’aluminium (Al3+) et environ 30 microgrammes de protéine vectrice CRM197.

Numéro d’autorisation: 68752

Swissmedic Date d’autorisation: 14 février 2023


Études cliniques

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) – ClinicalTrials.gov
NCT03950622

Publication:
Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, Morgan L, Shi Y, Pedley A, Musey LK, Buchwald UK. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022 Jan 3;40(1):162-172. doi: 10.1016/j.vaccine.2021.08.049. Epub 2021 Sep 8. PMID: 34507861.

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) – ClinicalTrials.gov
NCT03480763

Publication:
Song JY, Chang CJ, Andrews C, Diez-Domingo J, Oh MD, Dagan R, Hartzel J, Pedley A, Li J, Sterling T, Tamms G, Chiarappa JA, Lutkiewicz J, Musey L, Tu Y, Buchwald UK; V114-016 (PNEU-PATH) study group. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). Vaccine. 2021 Oct 15;39(43):6422-6436. doi: 10.1016/j.vaccine.2021.08.038. Epub 2021 Sep 4. PMID: 34489128.

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) – ClinicalTrials.gov
NCT02573181

Publication:
Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540-548. doi: 10.1080/21645515.2018.1532250. Epub 2018 Nov 14. PMID: 30427749; PMCID: PMC6605723.

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) – ClinicalTrials.gov
NCT03615482

Publication:
Severance R, Schwartz H, Dagan R, Connor L, Li J, Pedley A, Hartzel J, Sterling TM, Nolan KM, Tamms GM, Musey LK, Buchwald UK. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU). Hum Vaccin Immunother. 2022 Dec 31;18(1):1-14. doi: 10.1080/21645515.2021.1976581. Epub 2021 Nov 2. PMID: 34726574; PMCID: PMC8920144.

CH-PVC-00033, 05/2023